Eagle Pharmaceuticals Shareholders Still Have Time to Participate in the EGRX Class Action; Contact Robbins LLP Today
December 29, 2023 08:00 ET
|
Robbins LLP
Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue